Mode
Text Size
Log in / Sign up

SMART-HF guided workflow improved PAD control in adults with heart failure and implanted sensors.

SMART-HF guided workflow improved PAD control in adults with heart failure and implanted sensors.
Photo by Navy Medicine / Unsplash
Key Takeaway
Consider SMART-HF for PAD control in heart failure patients with sensors; safety data not reported.

This retrospective cohort study examined the impact of SMART-HF, a structured pulmonary artery diastolic pressure-guided workflow, in a community setting. The population consisted of adults with heart failure and an implanted pulmonary artery pressure sensor. The sample included 37 patients, of whom 36 had paired 90-day windows and 29 had paired 6-month windows for analysis.

Primary analysis focused on pulmonary artery diastolic pressure (PAD) control. Mean PAD at 90 days decreased from 18.3 +/- 7.0 to 16.1 +/- 6.3 mmHg, representing a mean reduction of -2.2 mmHg (P < 0.001). At 6 months, mean PAD decreased from 18.8 +/- 6.8 to 15.5 +/- 5.8 mmHg, a mean reduction of -3.3 mmHg (P < 0.001). Secondary outcomes included 90-Day Target HMPI achievement, reached in 26/36 patients (72.2%), and 6-Month Delta HMPI achievement, reached in 19/29 patients (65.5%; 95% CI 45.7-82.1).

Exploratory subgroup analyses assessed patients with baseline PAD >20 mmHg. At 90 days, mean PAD change was -2.9 +/- 3.6 mmHg (n=19; P = 0.002). At 6 months, mean PAD change was -4.9 +/- 4.9 mmHg (n=15; P = 0.002). Safety, tolerability, adverse events, discontinuations, and serious adverse events were not reported.

Limitations include the retrospective design and small sample size. The study suggests SMART-HF was associated with improved ambulatory pulmonary artery diastolic pressure control. Further evaluation is warranted, particularly for patients with elevated baseline pulmonary artery diastolic pressure.

Study Details

Study typeCohort
Sample sizen = 19
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Aims: Responses to remote pulmonary artery pressure data vary across programs. We evaluated SMART-HF, a structured pulmonary artery diastolic pressure (PAD)-guided workflow, in a community heart failure cohort. Methods: We retrospectively analysed adults with heart failure and an implanted pulmonary artery pressure sensor managed with SMART-HF. Pulmonary artery diastolic pressure (PAD) was calculated from prespecified 14-day windows at baseline, 90 days, and 6 months. Two hemodynamic management performance indices (HMPI) were prespecified: the 6-Month Delta HMPI (PAD reduction >2 mmHg from baseline) and the 90-Day Target HMPI (PAD [&le;]20 mmHg at 90 days). Exploratory analyses evaluated patients with baseline PAD >20 mmHg. Results: Of 37 patients, 36 had paired 90-day and 29 had paired 6-month windows. Mean PAD decreased from 18.3 +/- 7.0 to 16.1 +/- 6.3 mmHg at 90 days and from 18.8 +/- 6.8 to 15.5 +/- 5.8 mmHg at 6 months (both P < 0.001). The 90-Day Target HMPI was achieved in 26/36 (72.2%) and the 6-Month Delta HMPI in 19/29 (65.5%) [95% CI 45.7-82.1]. In the exploratory subgroup (baseline PAD >20 mmHg), mean PAD changes were -2.9 +/- 3.6 mmHg at 90 days (n = 19; P = 0.002) and -4.9 +/- 4.9 mmHg at 6 months (n = 15; P = 0.002). Conclusions: SMART-HF was associated with improved ambulatory pulmonary artery diastolic pressure control at 90 days and 6 months. Exploratory subgroup findings support further evaluation in patients with elevated baseline pulmonary artery diastolic pressure.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.